The donation commemorates the launch of TriLink’s first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price.
Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink’s ...
As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces ...
RNA viruses frequently bypass the conventional 5′ cap‐dependent mechanism of translation by employing alternative strategies that enable them to commandeer the host’s translational machinery. A ...
SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, today announced the launch of Prima RNApols ™ ExTend Cap AU ...
The success of the mRNA-based vaccines against SARS-CoV-2 merely hint at the healthcare implications of mRNA technology. More mRNA-based vaccines are in the works, as are mRNA-based therapeutics for ...
This article is based on a poster originally authored by Harrison H, Glen A , Andrews B, Bayle E, Duncan C, Fyfe M , Guest P, Rausch O , Swain C, Thomas B, Zemla-Brown A, Baric R, Chen Y, Froggatt H, ...
Through this agreement, Quantoom will be able to integrate TriLink’s CleanCap® mRNA capping technology into its Ntensify® platform, facilitating effective RNA synthesis and wider distribution of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback